Aperio to market Definiens Tissue Studio for advanced image analysis
17 May 2011
Digital pathology system supplier Aperio, and image
intelligence company Definiens have announced a partnership in which
Aperio will market Definiens Tissue Studio, an image analysis product
for quantitative digital pathology, on a worldwide, non-exclusive basis.
Image analysis provides automated quantitative analytical
techniques to help pathologists interpret pathology slides, which
informs treatment decisions and improves patient care.
Definiens Tissue Studio will be integrated into Aperio’s
applications framework and accessible through its Spectrum
information management system to expand the existing suite of image
analysis tools that include Area Quantification, Cell
Quantification, Microvessel Analysis, Rare Event Detection and Genie
Histology Pattern Recognition. The Spectrum system includes viewing
tools and enables the execution of analysis applications in a
geographically distributed environment for maximum throughput.
“This alliance furthers our ability to significantly improve
intra- and inter-observer agreement and patient care by providing
the most scalable and highest performance digital pathology
solutions available,” said Dirk G. Soenksen, CEO of Aperio. “We are
excited that Definiens recognizes the value of leveraging their
leading image analysis software on the industry’s most robust
digital pathology platform.”
“Digital pathology is becoming an essential technology for
increasing productivity and improving treatment decisions,” said
Thomas Heydler, CEO of Definiens. “Automated image analysis is the
next step in digital pathology, providing clinicians with greater
insight into patients’ disease states. Definiens Tissue Studio is a
natural fit for Aperio’s platform, and we expect to reach a wide
customer base as a result of this partnership.”